GT Biopharma (GTBP) Enterprise Value (2016 - 2021)
GT Biopharma (GTBP) has disclosed Enterprise Value for 12 consecutive years, with -$29.9 million as the latest value for Q3 2021.
- On a quarterly basis, Enterprise Value fell 5667.05% to -$29.9 million in Q3 2021 year-over-year; TTM through Sep 2021 was -$29.9 million, a 5667.05% decrease, with the full-year FY2020 number at -$5.5 million, down 2674.62% from a year prior.
- Enterprise Value was -$29.9 million for Q3 2021 at GT Biopharma, up from -$39.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$39000.0 in Q2 2017 to a low of -$39.5 million in Q2 2021.
- A 5-year average of -$6.4 million and a median of -$882500.0 in 2017 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: skyrocketed 92.76% in 2019, then tumbled 15833.33% in 2021.
- GT Biopharma's Enterprise Value stood at -$745000.0 in 2017, then plummeted by 88.05% to -$1.4 million in 2018, then skyrocketed by 85.94% to -$197000.0 in 2019, then crashed by 2674.62% to -$5.5 million in 2020, then tumbled by 447.59% to -$29.9 million in 2021.
- Per Business Quant, the three most recent readings for GTBP's Enterprise Value are -$29.9 million (Q3 2021), -$39.5 million (Q2 2021), and -$27.7 million (Q1 2021).